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The aim of this study was to evaluate the presence of early
vascular damage in young normal-weight women with poly-
cystic ovary syndrome (PCOS).
Thirty young normal-weight women with PCOS, who had
no additional metabolic or cardiovascular diseases, and 30
healthy women (controls) matched for age and body mass
index were studied. A complete hormonal assay was per-
formed in each subject. Serum insulin and glucose levels were
measured at baseline and after the oral glucose tolerance test.
Plasma endothelin-1 levels and serum lipid profile were also
assessed. The endothelial function was studied by flow-medi-
ated dilation on the brachial artery, and arterial structure
was evaluated by intima-media thickness measurement using
Doppler ultrasound of both common carotid arteries.
A significant (P < 0.05) difference in flow-mediated dilation
(14.3  1.9% vs. 18.1  2.0% for PCOS patients and controls,
respectively) and in intima-media thickness (0.53  0.09 mm
vs. 0.39  0.08 mm for PCOS patients and controls, respec-
tively) was found between PCOS and control subjects. Serum
endothelin-1 levels were also significantly (P < 0.05) higher in
PCOS patients compared with controls (1.1  0.4 pmol/liter
vs. 0.5  0.2 pmol/liter for PCOS patients and controls,
respectively).
In conclusion, our data show that young, normal-weight,
nondyslipidemic, nonhypertensive women with PCOS have
an early impairment of endothelial structure and function.
(J Clin Endocrinol Metab 89: 4588–4593, 2004)
POLYCYSTIC OVARY SYNDROME (PCOS) is a commonendocrine-metabolic disease that occurs in up to 10% of
reproductive-age women (1, 2). PCOS is considered not only
a reproductive endocrinopathy but also a metabolic disorder
associated with long-term health risks, including diabetes
mellitus (3–5) and coronary artery disease (6–8). In partic-
ular, insulin resistance, hyperandrogenemia, and dyslipide-
mia are likely the major risk factors for the occurrence of
cardiovascular disease (CVD) in PCOS (9–11). These cardio-
vascular risk factors are often evident at an early age (12, 13),
suggesting that women with PCOS represent a large group
of women at increased risk for developing early-onset CVD.
One of the early signs of cardiovascular lesions is the endo-
thelial injury (9, 14, 15). Several authors (16–18) have reported
precocious anatomical and functional arterial changes in PCOS
women. The insulin resistance could play a key role in the
development of endothelial damage (16, 19–22), which repre-
sents an early sign of atherosclerosis (15, 23).
Vascular changes can be noninvasively examined by the
intima-media thickness (IMT) of carotid arteries and by flow-
mediated dilation (FMD) of brachial arteries. IMT of the
common carotid artery is a morphological marker of preco-
cious atherosclerosis (24–26), and it has been associated with
both elevated androgen levels and insulin resistance (27, 28).
In addition, the assessment of FMD of the brachial artery has
been widely used as method of determining endothelial
function (29).
Among the several circulating endothelium-derived vaso-
active molecules, endothelin (ET)-1 is considered one of the best
known markers of abnormal vascular reactivity (30, 31). Ele-
vated serum levels of ET-1 have been reported in some insulin-
resistant states (32, 33) and recently also in PCOS (34).
At present, no data are available on either the functional
or biochemical evaluation of endothelium in women with
PCOS. Therefore, the aim of the present study was to inves-
tigate the endothelial function, arterial structure, and serum
ET-1 levels in a population of young PCOS women.
Subjects and Methods
Subjects
Thirty young normal-weight women with PCOS and 30 age- and
body mass index (BMI)-matched controls were enrolled in this study.
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A BMI between 18 and 25 was considered as the index of normal
weight (35).
The diagnosis of PCOS was made by anovulatory infertility (con-
firmed by luteal progesterone assay) and normal serum FSH levels
(normal range, 1.0 –10.0 IU/liter) and at least two of the following
features: hirsutism (Ferriman-Gallwey score 8) (36), elevated serum
androgen levels [total testosterone (T)  2 nmol/liter, and/or an-
drostenedione (4-A)  15 nmol/liter, and/or dehydroepiandros-
terone sulfate (DHEA-S)  10 mol/liter], LH to FSH ratio greater
than 2, and polycystic ovaries identified by transvaginal ultrasonog-
raphy (TV-USG) examination (37). All the patients achieved National
Institute of Child Health and Human Development criteria for PCOS
(38). Table 1 shows the clinical and biochemical diagnostic features
of the women with PCOS.
The control group consisted of healthy volunteer females who had
regular menstrual cycles (defined as 26–32 d in length). Their healthy
state was determined by medical history, physical and pelvic exami-
nation, and complete blood chemistry. The normal ovulatory state was
confirmed by TV-USG and plasma progesterone levels during the luteal
phase of the cycle.
Exclusion criteria for all subjects included age less than 18 or greater
than 25 yr, pregnancy, hypothyroidism, hyperprolactinemia, Cushing’s
syndrome, nonclassical congenital adrenal hyperplasia, and current or
previous (within the last 6 months) use of oral contraceptives, glucocor-
ticoids, antiandrogens, ovulation induction agents, antidiabetic and an-
tiobesity drugs, or other hormonal drugs. Women with clinical and/or
biochemical hyperandrogenism alone were excluded from the control
group.
PCOS and control women with glucose intolerance, as assessed by
World Health Organization criteria (39), were excluded from the study.
None of the subjects were affected by any neoplastic, metabolic,
hepatic, and cardiovascular disorder or other concurrent medical illness
(i.e. diabetes, renal disease, and malabsorptive disorders). All subjects
were nonsmokers and had a normal physical activity level; none drank
alcoholic beverages.
Study protocol
The procedures used were in accordance with the guidelines of the
Helsinki Declaration on human experimentation. The study was ap-
proved by the Institutional Review Board of the University “Federico II”
of Naples. The purpose of the protocol was explained both to the patients
and control women, and a written consent was obtained from them
before beginning the study.
At study entry, all subjects had venous blood drawn to perform the
genetic study and to evaluate the complete hormonal assays, lipid pro-
file, and ET-1, glucose, insulin, and homocysteine (Hcy) levels. Glucose
and insulin values were detected also after oral glucose tolerance tests
(OGTT). To evaluate the hyperandrogenetic state, free androgen index
(FAI) was also calculated (40). During the same visit, all subjects un-
derwent TV-USG, anthropometric measurements, cardiovascular as-
sessment, and echocolor-Doppler evaluation.
The anthropometric measurement included height, weight, BMI
(kg/m2), and waist to hip ratio (WHR). BMI was measured as the ratio
between the weight and the square of the height. WHR was calculated
as the ratio between the smallest circumference of the torso (between the
twelfth rib and the iliac crest) and the circumference of the hip (con-
sidered as the maximal extension of the buttocks). All measurements
were performed when the patients were in standing position with re-
laxed abdomen, arms at sides, and joined feet (41).
Measurements of heart rate (HR), systolic blood pressure (SBP), and
diastolic blood pressure (DBP) were evaluated by standard methods.
SBP and DBP were measured in the right arm, with the subjects in a
relaxed sitting position. The average of six measurements (three mea-
surements taken by each of two examiners) with a mercury sphygmo-
manometer was used (42).
A semiquantitative questionnaire was used to evaluate patients’ daily
physical activities, jobs, and daily activities. Physical activity was ex-
pressed as a score ranging from 1 to 3. A score of 3 was assigned to
women who exercised regularly (high physical activity); a score 2 of was
assigned to women who did not exercise regularly but who participated
daily in activities like house cleaning, climbing stairs, or walking to
work, to the bus stop, or to a restaurant (moderate physical activity); a
score of 1 was assigned to women who did not participate in any of
above-mentioned activities (low physical activity) (43).
The data regarding the echocardiographic assessments will be shown
elsewhere.
Biochemical assays
All blood samples were obtained in the morning between 0800 h and
0900 h after an overnight fast and when the subject was resting in bed
during the early follicular phase (d 2–5) of the spontaneous or proges-
terone-induced menstrual cycle. Blood samples (5 ml) were collected in
tubes containing EDTA after a 12-h fast and a 30-min resting period in
the supine position. The samples were immediately centrifuged at 4 C
for 20 min at 1600  g, and plasma samples were stored at 20 C.
Plasma LH, FSH, prolactin, estradiol, progesterone, 17-hydroxy-
progesterone, T, 4-A, and DHEA-S were measured by specific RIA
as previously reported (44 – 49). SHBG levels were measured using an
immunoradiometric assay (48). Serum insulin was measured by
a solid-phase chemiluminescent enzyme immunoassay using com-
mercially available kits (Immunolite Diagnostic Products Co., Los
Angeles, CA) (48).
Glucose and insulin concentrations were also measured 30 min after
insertion of the iv catheter to detect the fasting levels (time 0) before
OGTT. Successively, each subject received an oral 75-g glucose load.
Further blood samples (10 ml each) were obtained at 30-min intervals for
the following 3 h during the infusion period (times 30, 60, 90, and 120),
and glucose and insulin concentrations were determined. Blood glucose
levels were determined by the glucose oxidase method (45). The glucose
and insulin response to OGTT was also analyzed by calculating the area
under the curve (AUC). The AUCglucose to AUCinsulin ratio was also
calculated in each subject (50).
The serum total cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides
(TG) levels were measured with an autoanalyzer (Monarch 1000; In-
strumentation Laboratory, Milan, Italy) using commercial kits (IL TEST;
Instrumentation Laboratory) (51). The LDL-C was evaluated using the
following formula: TC  HDL-C  1/5 TG.
Serum ET-1 was measured by ELISA (Biomedica Gesellschft, Wien,
Austria), with a sensitivity of 0.05 pmol/liter and intra- and interassay
coefficients of variation (CV) of 4.5 and 6.9%, respectively. Normal ET-1
levels ranged between 0.2 and 0.7 pmol/liter, and the recovery mea-
sured with two levels of synthetic ET-1 was 95% in samples with 0.5
pmol/liter and 104% in samples with 2 pmol/liter. The cross-reactivity
with ET-3 and Big ET was estimated as less than 5% and less than 1%,
respectively.
Serum Hcy levels were measured by HPLC as previously described (49).
Brachial artery study
Vascular reactivity was assessed using brachial artery ultrasound. A
7.5-MHz linear phased array ultrasound transducer (Vingmed System
Five; GE, Horten, Norway) was used to image the dominant brachial
artery longitudinally just above the antecubital fossa (41).
TABLE 1. Clinical and biochemical diagnostic features of the
30 PCOS women studied
Features No. of women %
Anovulatory infertility 30 100
Normal FSH levels 30 100
Oligo/amenorrheaa 30 100
Clinical hyperandrogenisma 27 90
Hirsutismb 27 90
Acne 7 23.3
Biochemical hyperandrogenisma 11 36.7
T  2 nmol/liter 9 30
4-A  15 nmol/liter 8 26.7
DHEA-S  10 mol/liter 8 26.7
LH/FSH ratio  2 28 93.3
Polycystic ovary at TV-USG 23 76.7
a National Institutes of Health PCOS criteria.
b As evaluated by Ferriman-Gallwey score.
Orio et al. • PCOS and Endothelial Function J Clin Endocrinol Metab, September 2004, 89(9):4588–4593 4589
Subjects were asked to fast for at least 8–12 h and to refrain from
physical activity for at least 4–6 h before the examination. All hemo-
dynamic measurements were obtained with the subjects in a supine
comfortable position in a quiet, temperature-controlled room. In all
studies, blood pressure in the contralateral brachial artery was recorded
at regular intervals, and the electrocardiogram was monitored contin-
uously. After baseline images of brachial arterial diameter were ob-
tained, limb flow occlusion was produced by inflating a standard sphyg-
momanometry cuff on the upper arm to 40 mm Hg above SBP for 4 min.
This caused ischemia and consequent dilatation of downstream resis-
tance vessels. Subsequent cuff deflation induced a brief high-flow state
through the brachial artery (reactive hyperemia) for the release of en-
dothelial nitric oxide to accommodate the dilated resistance vessels. The
brachial artery diameter was measured at 30 sec, and 1, 2, 3, and 4 min
after ischemia (41).
All images were recorded on videotape for subsequent off-line anal-
ysis. FMD of the brachial artery was expressed as the percentage change
in the arterial diameter from baseline to 4 min after deflation cuff. The
FMD was used as a measure of endothelium-dependent vasodilatation.
In our studies, the intra- and interobserver CV for the repeated mea-
surements of resting arterial diameter were 2.3 and 5.6%, respectively.
Carotid artery study
Longitudinal ultrasonographic scans of the carotid artery were ob-
tained on the same day as the studies of brachial artery reactivity. All
women were examined in the supine position, with the head hyperex-
tended and turned away from the side being scanned. Scans were per-
formed by an experienced ultrasonographer (B.D.S.), who was blinded
to clinical data, using a color Doppler (Vingmed System Five; GE) with
a high-resolution 10-MHz linear probe. The sonographer scanned the
right and left common carotid artery and the carotid bifurcation-bulb
area from multiple planes (lateral, anterior oblique, and posterior
oblique). Images were obtained from the distal portion of both common
carotid arteries, 1–2 cm proximal to the carotid bulb and immediately
proximal to the origin of the bifurcation. To simplify the scanning pro-
cedure and because of the lesser stability of measurements of the internal
and external carotid artery, these segments were not taken into consid-
eration in the present study (52, 53). The IMT of the posterior (far) wall
of both common carotid arteries was measured as the distance between
the junction of the lumen and intima and the junction of the media and
adventitia (24, 53, 54).
The IMT was measured at the end-diastole from the B-mode screen.
The mean IMT for each side was calculated as the average of 10 mea-
surements made in the right and left carotid arteries using electronic
calipers. Ambient light and temperature were controlled throughout the
procedure. In our studies, the intra- and interobserver CV for the re-
peated measurements of IMT were 7.0 and 12.0%, respectively.
Statistical analysis
Continuous data were expressed as mean  sd. A P  0.05 was
considered statistically significant. The SPSS 11.0 (SPSS Inc., Chicago, IL)
package was used for statistical analyses.
The comparisons among controls and patients in demographic and
biochemical data were performed by the Student’s t test for unpaired
data. All parameters were adjusted for chronological age, BMI, WHR,
smoking status, glucose and insulin levels, FAI, lipid profile, Hcy con-
centrations, and SBP and DBP.
Stepwise multiple linear regression analysis was performed to test
separately each of the primary end points (FMD, IMT, and ET-1) against
the independent variables of chronological age, BMI, WHR, AUCglucose
to AUCinsulin ratio, Hcy levels, FAI, lipid concentrations, and SBP and
DBP.
Results
Patient characteristics and hormonal profile are presented
in Table 2. The groups were adequately and closely matched
for age and BMI. The Ferriman-Gallwey scores were signif-
icantly (P 0.05) higher in PCOS patients than in the control
group. A significant (P  0.05) difference was observed for
LH, progesterone, 17-hydroxyprogesterone, T, 4-A,
DHEA-S, and SHBG. The FAI was also significantly higher
in PCOS group than in control group (P  0.05; Table 2).
Table 3 shows the metabolic data of women with PCOS
and controls. Serum vitamin B12, folate, and Hcy concentra-
tions were similar between the two groups (Table 3). In
addition, no differences were detected in fasting glucose and
in AUCglucose levels between the groups; however, fasting
insulin levels, AUCinsulin, and AUCglucose to AUCinsulin ratio
were significantly (P 0.05) higher in PCOS patients than in
control women (Table 3). No differences in serum TC,
LDL-C, HDL-C, and TG levels were detected between the
PCOS and control groups (Table 3).
No difference was observed in heart rate, SBP, and DBP
between PCOS patients and control women (Table 4). More-
over, artery diameters at baseline (3.24  0.3 mm vs. 2.96 
0.4 mm for PCOS patients and controls, respectively) and
after reactive hyperemia (3.7  0.3 mm vs. 3.5  0.2 mm for






Age (yr) 22.2  2.5 22.6  2.3
BMI (kg/m2) 22.4  2.1 22.1  1.8
WHR 0.77  0.4 0.72  0.3
Ferriman-Gallwey score 12.1  1.3a 4.5  0.9
Physical activity scoreb 2.0  0.3 2.1  0.4
FSH (IU/liter) 10.5  1.2 8.8  1.3
LH (IU/liter) 24.6  3.7a 11.6  1.5
PRL (ng/ml) 11.5  1.9 10.8  1.3
E2 (pmol/liter) 117.9  28.1 109.8  31.3
P (nmol/liter) 1.2  0.5a 1.9  0.7
17-OHP (nmol/liter) 1.9  0.2a 0.7  0.1
T (nmol/liter) 2.6  0.4a 1.0  0.2
4-A (nmol/liter) 5.18  0.7a 2.14  0.5
DHEA-S (mol/liter) 4535  527a 2988  311
SHBG (nmol/liter) 28.1  5.1a 50.5  8.6
FAI 14.6  7.6a 3.2  1.6
Data are expressed as mean SD. PRL, Prolactin; E2, estradiol; P,
progesterone; 17-OHP, 17-hydroxyprogesterone.
a P  0.05 vs. control group.
b Physical activity score: 1, low; 2, moderate; 3, high.






Vitamin B12 (ng/ml) 375.4  113.9 392.1  135.1
Folate (nmol/ml) 8.4  2.2 8.6  2.3
Hcy (mol/liter) 10.4  2.7 10.2  2.5
Fasting glucose (mmol/liter) 6.1  2.1 5.4  1.9
Fasting insulin (U/ml) 18.8  5.5a 6.9  2.0
OGTT
AUCglucose 1109  531 1093  449
AUCinsulin 5404  1227
a 2278  496
AUCglucose to AUCinsulin ratio 0.21  0.31
a 0.48  0.37
TC (mmol/liter) 3.96  0.12 3.94  0.12
LDL-C (mmol/liter) 1.79  0.16 1.78  0.14
HDL-C (mmol/liter) 2.85  0.23 2.81  0.20
TG (mmol/liter) 1.23  0.20 1.22  0.19
Data expressed as mean  SD.
a P  0.05 vs. control group.
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PCOS patients and controls, respectively) were significantly
(P  0.05) different between the PCOS and control groups.
A significant (P 0.05) difference in FMD (14.3 1.9% vs.
18.1 2.0% for PCOS patients and controls, respectively) and
IMT (0.53  0.09 mm vs. 0.39  0.08 mm, for PCOS patients
and controls, respectively) was found between PCOS and
control women (Table 4). Serum ET-1 levels were also sig-
nificantly (P 0.05) higher in PCOS patients when compared
with controls (1.1  0.4 pmol/liter vs. 0.5  0.2 pmol/liter,
respectively; Table 4).
In women with PCOS, stepwise multiple linear regression
analysis showed a direct relationship between FMD and
AUCglucose to AUCinsulin ratio (P 0.013), IMT and FAI (P
0.045), and ET-1 and SBP (P  0.001; Table 5). An inverse
linear relationship was found between ET-1 and AUCglucose
to AUCinsulin ratio (P  0.001; Table 5). No relationship was
found in controls.
Discussion
PCOS is characterized by several metabolic alterations that
could increase the risk of CVD (9, 55, 56), and one of the early
signs of cardiovascular lesions is the endothelial injury (24).
This study was carried out to clarify the exact relationships
between vascular damage and PCOS. In fact, here we inves-
tigate the functional and structural vascular damage in PCOS
by serum ET-1 assay and both carotid IMT and brachial
artery FMD evaluation.
Our data demonstrated that women with PCOS had
higher ET-1 levels and IMT than controls, whereas they
showed reduced FMD values.
Some authors (57, 58) have postulated that ET-1, as a
precocious marker of CVD, could contribute to the athero-
sclerotic process. In addition, circulating ET-1 levels have
been shown to be increased in patients with obesity (59, 60),
atherosclerosis (57, 58), myocardial infarction (57, 61), dia-
betes mellitus (33, 60), and, more recently, PCOS (34).
Specifically, hyperinsulinemic women with PCOS have a
significant risk of early CVD (22, 23), and this risk seems to
be further increased by the stimulating effects of insulin on
ET-1 secretion (32). Furthermore, ET-1 is considered as an
additional risk factor in nonobese hypertensive subjects with
metabolic abnormalities (24), and PCOS women represent an
intriguing biological model that can illustrate metabolic and
hormonal effects on the endothelium without overt cardio-
vascular risk factors.
According to Diamanti-Kandarakis et al. (34), we found
that serum ET-1 levels were significantly higher in normal-
weight women with PCOS than in BMI-matched healthy
controls, suggesting that increased ET-1 concentrations are a
feature of PCOS independent of obesity. A putative cause of
the increased ET-1 levels in PCOS could be the insulin re-
sistance. In fact, it was considered a prominent abnormality
in both obese and lean patients with hyperandrogenism and
PCOS (62). In support of our hypothesis, several studies (7,
20) have shown that hyperinsulinemia is a predictor of cor-
onary artery disease and that insulin stimulates secretion of
ET-1 in vivo and in vitro (32).
Recently, Migdalis et al. (63) investigated the possible re-
lationship between ET-1 and arterial wall thickness in dia-
betic subjects and revealed not only that elevated ET-1 levels
are present in patients with increased IMT but also that ET-1
is the main associate of the change of IMT value (64).
At present, IMT is the best-studied ultrasonographic
marker for early atherosclerotic vascular wall lesions (24, 25,
65). A direct correlation between IMT and the risk of myo-
cardial infarction and stroke in patients without a history of
vascular disease has been shown (66). Several metabolic al-
terations, such as obesity (67, 68), insulin resistance (28, 69),
and hyperandrogenism (70), have been widely accepted as
risk factors for increased IMT.
IMT has been already considered a potential marker of risk
for CVD in women with PCOS (17). In particular, Talbott et al.
(17) showed an association between PCOS and premature
carotid atherosclerosis in middle-aged women, demonstrat-
ing a BMI-independent difference in carotid IMT between
middle-aged women with PCOS and controls, but not in
younger women. Conversely, our data show an increased
IMT even in young women with PCOS and demonstrate that,
in PCOS, the increased IMT is not due to a prolonged ex-
posure to an adverse cardiovascular profile.
Our study population was not only young women, but it
also included women who were of normal weight, nondys-
lipidemic, and nonhypertensive. A significant difference in
insulin resistance and in androgen levels was observed be-
tween PCOS patients and controls, suggesting an important
role for the exposure of androgens or insulin in the most
precocious development of atherosclerosis. Previous studies
(66, 70–72) have demonstrated the importance of sex hor-
TABLE 4. Structural and functional parameters of cardiovascular





HR (bpm) 78.3  3.9 76.2  4.2
SBP (mm Hg) 111.3  8.2 113.2  6.7
DBP (mm Hg) 74.2  4.7 71.4  4.3
Baseline artery diameter (mm) 3.24  0.3a 2.96  0.4
Diameter after reactive
hyperemia (mm)
3.7  0.3a 3.5  0.2
FMD (%) 14.3  1.9a 18.1  2.0
IMT (mm) 0.53  0.09a 0.39  0.08
ET-1 (pmol/liter) 1.1  0.4a 0.5  0.2
All data (expressed as mean  SD) were adjusted for chronological
age, BMI, WHR, smoking status, glucose and insulin levels, FAI, lipid
profile, Hcy concentrations, and SBP and DBP. HR, Heart rate.
a P  0.05 vs. control group.
TABLE 5. Final models of stepwise multiple linear regression
analysis in PCOS patients to test separately each of our primary
end points against the main independent variables
Variable Coefficient  P
FMD
AUCglucose to AUCinsulin ratio 4.179 0.449 0.013
Constant 13.419
IMT
FAI 0.004 0.369 0.045
Constant 0.469
ET-1
AUCglucose to AUCinsulin ratio 1.254 0.638 0.001
SBP 0.021 0.432 0.001
Constant 0.978
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mones in contributing to carotid arterial wall thickness. Hy-
perandrogenemia in women with PCOS may result in a male
pattern of lipoproteins, suggesting an increased atherogenic
potential in PCOS patients (73). In addition, Lakhani et al. (74)
evidenced impaired carotid viscoelastic properties in PCOS
women, providing additional evidence of vascular dysfunc-
tion in women with this syndrome (75).
Data regarding endothelial dysfunction in PCOS pa-
tients are poor and contrasting (16, 18, 75). Mather et al.
(75) showed no difference in FMD between PCOS patients
and controls, despite the hyperandrogenism and insulin
resistance of PCOS patients. Conversely, Paradisi et al. (18)
showed markedly diminished endothelium-dependent
and insulin-mediated flow responses in the femoral artery
of women with PCOS. Recently, Kelly et al. (16) demon-
strated an increased vascular stiffness and a functional
defect in the vascular action of insulin in PCOS patients.
In conclusion, our data show that young, normal-weight,
nondyslipidemic, nonhypertensive women with PCOS have
altered endothelial function and increased IMT and serum
ET-1 values, suggesting early functional, structural, and bio-
chemical preatherosclerotic vascular impairment.
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